

RECORDATI: UPDATE ON THE EXECUTION OF THE SHARE BUY-BACK PROGRAM

Milan, 12th January 2022 – Within the Recordati's share buy-back program communicated to the market on 29th October 2021 and initiated on 1st November 2021, as per authorization granted by the Shareholders' Meeting held on 20th April 2021, with the object of the servicing of current and future stock option plans in favour of Recordati Group's management, the Company communicates the following purchase transactions of Recordati shares pursuant to art. 2, paragraph 3, of the EU Delegated Regulation 2016/1052/UE, on the basis of the information provided by J.P. Morgan AG as intermediary in charge of executing, in full independency ('riskless principal'), the share buy-back program on behalf of the Company.

Aggregate details of daily transactions made on 6th and 7th January 2022¹ in Recordati ordinary shares (ISIN IT0003828271) are as follows:

SUMMARY OF PURCHASE TRANSACTIONS FROM 6 th JANUARY 2022 TO 7 th JANUARY 2022				
Date	Type of Transaction	Quantity	Weighted average price (Euro)	Exchange
06/01/2022	Purchase	2,366	53.8393	MTA
07/01/2022	Purchase	53	53.8200	MTA
TOTAL		2,419	53.8389	

The details of all the purchase transactions carried out in the period indicated above are reported in the following pages.

On 7th January 2022, the Company held no. 3,216,719 treasury shares which amount to 1.537% of the current share capital.

***Recordati**, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in Europe, Russia and the other C.I.S. countries, Ukraine, Turkey, North Africa, the United States of America, Canada, Mexico, some South American countries, Japan and Australia. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in several therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2020 was € 1,448.9 million, operating income was € 469.0 million and net income was € 355.0 million.*

For further information:

¹ For sake of clarity it should be noted that the Company did not make any transactions from 11th December 2021 to 5th January 2022.

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Registered Office

Via Matteo Civitali, 1
20148 Milano, Italy
Ph. (39) 02 487871
Fax (39) 02 40073747
www.recordati.com

Share Capital € 26.140.644,50 fully paid-up
Milano, Monza, Brianza and Lodi Comp. Reg. No. 00748210150
Tax Code/VAT No. 00748210150
Milano R.E.A. No. 401832

Company subject to the Management and Coordination Activity of Rossini Luxembourg S.à.r.l

Recordati website: www.recordati.it/en

Investor Relations

Federica De Medici

(39) 02 48787146

e-mail: investorelations@recordati.it

Investor Relations

Lucia Abbatantuoni

(39) 02 48787213

e-mail: investorelations@recordati.it

Ufficio Stampa

Brunswick - Barbara Scalchi / Andrea Mormandi

(39) 02 9288 6200

e-mail: recordati@brunswickgroup.com

Attachment:
Daily details of transactions

Trade Date	Trade Time GMT	Currency	Exchange	Trade Price	Quantity
06-gen-22	08:07:45	EUR	MTA	54	50
06-gen-22	08:07:45	EUR	MTA	54	43
06-gen-22	08:08:42	EUR	MTA	53,92	28
06-gen-22	08:11:59	EUR	MTA	53,8	38
06-gen-22	08:12:46	EUR	MTA	53,8	6
06-gen-22	08:13:42	EUR	MTA	53,8	44
06-gen-22	08:16:05	EUR	MTA	53,74	72
06-gen-22	08:16:41	EUR	MTA	53,76	49
06-gen-22	08:19:16	EUR	MTA	53,96	90
06-gen-22	08:20:37	EUR	MTA	54	73
06-gen-22	08:20:37	EUR	MTA	54	108
06-gen-22	08:23:50	EUR	MTA	53,94	46
06-gen-22	08:24:51	EUR	MTA	53,92	46
06-gen-22	08:26:35	EUR	MTA	53,78	43
06-gen-22	08:30:04	EUR	MTA	53,74	43
06-gen-22	08:33:23	EUR	MTA	53,68	97
06-gen-22	08:34:42	EUR	MTA	53,68	85
06-gen-22	08:34:42	EUR	MTA	53,64	122
06-gen-22	08:36:53	EUR	MTA	53,78	28
06-gen-22	08:37:03	EUR	MTA	53,78	74
06-gen-22	08:37:07	EUR	MTA	53,76	95
06-gen-22	08:38:49	EUR	MTA	53,78	67
06-gen-22	08:38:49	EUR	MTA	53,76	84
06-gen-22	08:39:27	EUR	MTA	53,84	42
06-gen-22	08:39:27	EUR	MTA	53,84	26
06-gen-22	08:39:27	EUR	MTA	53,82	47
06-gen-22	08:41:17	EUR	MTA	53,76	70
06-gen-22	08:44:04	EUR	MTA	53,8	42
06-gen-22	08:44:04	EUR	MTA	53,78	46
06-gen-22	08:45:21	EUR	MTA	53,9	50
06-gen-22	08:45:44	EUR	MTA	53,88	46
06-gen-22	08:46:05	EUR	MTA	53,9	42
06-gen-22	08:49:10	EUR	MTA	53,9	59
06-gen-22	08:49:10	EUR	MTA	53,88	59
06-gen-22	08:49:10	EUR	MTA	53,86	55
06-gen-22	08:51:15	EUR	MTA	53,92	56
06-gen-22	08:51:48	EUR	MTA	53,9	43

06-gen-22	08:53:28	EUR	MTA	53,88	42
06-gen-22	08:54:43	EUR	MTA	53,9	10
06-gen-22	15:14:10	EUR	MTA	53,94	47
06-gen-22	15:14:10	EUR	MTA	53,94	50
06-gen-22	16:03:25	EUR	MTA	53,94	40
06-gen-22	16:03:26	EUR	MTA	53,94	43
06-gen-22	16:03:26	EUR	MTA	53,94	20
07-gen-22	08:01:00	EUR	MTA	53,82	53